40 pharmaceutical companies in Connecticut

The pharmaceutical companies in Connecticut have a strong track record of growth and success.

It is a critical sector that demonstrates Connecticut’s economy is technology-driven and well-positioned for future growth Many of the pharmaceutical companies in Connecticut are developing truly cutting-edge therapies, products, and technologies that help treat people today and will undoubtedly play a significant role in improving medicine and quality of care in the future.

Pharma is big in Connecticut; more than 18,000 Connecticut residents work at over 40 different pharmaceutical companies providing different pharmaceutical jobs in ct.

Pfizer, Biohaven, and Boehringer Ingelheim have headquarters in Connecticut and invest more than $6 billion per year in pharmaceuticals.

Indeed, as part of Connecticut’s commitment to pharma, the state has established CURE, a cluster comprised of pharmaceutical and biotech companies.

Innovations of Connecticut Pharmaceuticals

Connecticut is embracing a new strategic vision for its pharmaceutical sector that could result in the creation of more than 6,000 new jobs over the next ten years as the state competes with neighboring New York and Massachusetts, both of which have thriving pharmaceutical and biotech industries.

Connecticut’s pharmaceutical sector employed 18,000 people across over 40 companies. Stakeholders have chosen six key areas of growth for the pharmaceutical industry.

Investment, infrastructure, recruitment, resource building, talent pipeline (from c-suite to bench), and marketing and branding are among the areas being groomed for growth.

During the first half of 2019, state lawmakers and key industry stakeholders collaborated to drive Connecticut’s development as a viable state for the life science industry.

The state working group stated in its announcement that it will collaborate to create a “vibrant ecosystem between sciences and the growing areas of digital health, medical devices, technology, as well as artificial intelligence and machine learning.”

It’s a significant move because it has the potential to attract business from neighboring New York, which may be looking for a less expensive option for real estate.

The two neighboring states New York and Massachusetts have had much greater success growing their pharmaceutical industries over the last decade.

New York City and the Boston metropolitan area have emerged as key pharmaceutical hubs in New England. During the same 10-year period, Connecticut lost two major anchor companies, Bayer and Bristol-Myers Squibb.

Despite those losses, large pharmaceutical and biotech companies in connecticut continue to have a significant footprint on the local economy.

According to the trade organization, Boehringer Ingelheim and Pfizer, for example, are committed to remaining in the state and are supportive of the industry and workforce.

The state has the sixth-highest number of scientists and engineers per capita in the country. Aside from the degrees sought in the sciences, Connecticut has a highly educated workforce, ranking third in the adult population with advanced degrees.

The state is well-positioned to grow pharmaceuticals, but there is still much work to be done. Collaboration is essential to ensuring that all stakeholders are working synergistically and making strategic investment decisions.

Several Connecticut-based companies worked on a vaccine, including the CaroGen Corporation. Since the pandemic’s early stages, the Farmington-based vaccine and immunology therapy company began working on a formula.

Pharmaceutical Companies in Connecticut

Here’s a list of some of the pharmaceutical companies in Connecticut:

Ai Therapeutics, Inc.

Address: 530 Old Whitfield St Guilford, CT, 06437-3441 United States

Phone: (203) 458-7100

Innovations of Connecticut Pharmaceuticals

Pharmaceutical Companies in Connecticut

Faqs about the pharmaceutical companies in Connecticut

A final thought about the pharmaceutical companies in Connecticut

Editors’ Picks

Leave a Reply Cancel reply